

imi-rhapsody.eu


This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115881.

This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

IMI2 is the world biggest public private partnership in life science.

Participants from Switzerland receive funding from the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 16.0097.

Assessing risk and progression of pre-diabetes and type 2 diabetes to enable disease modification.



RHAPSODY is a unique collaboration of over 100 researchers from academic, clinical and pharmaceutical research institutions. This project studies the progression of pre-diabetes to type 2 diabetes, the most frequent form of diabetes as well as the rate and impact of diabetes deterioration.

Diabetes is a pandemic disease, which currently affects 420 million people worldwide. Type 2 diabetes is characterised by an increase in blood glucose (sugar) levels, since the body is not able to effectively use the glucose as an energy source. Unfortunately, the effectiveness of current therapies varies considerably between individuals. Tailoring medical therapies to the patient's biological characteristics may help optimize disease prevention or treatment, thereby improving overall prognosis and reducing costs and side effects.

RHAPSODY brings together leading experts and resources in the field of type 2 diabetes, in particular unique collections of genetic, biochemical and clinical data as well as expertise in regulatory approval, health economics and patient engagement. Combining new and existing data, RHAPSODY will study the diversity of mechanisms leading to diabetes and its deterioration and identify novel biomarkers (measurable indicators of a biological state or condition) to stratify patients, ultimately leading to precision therapy and prevention of diabetes.

imi-rhapsody.eu
info@imi-rhapsody.eu
0041 21 694 04 12



Our Consortium

Université de Lausanne Switzerland
Lunds Universitet Sweden
Technische Universität Dresden Germany
Università di Pisa Italy
Université de Paris France
INSERM France
Université Libre de Bruxelles Belgium
Institut Suisse de Bioinformatique Switzerland
University of Oxford United Kingdom
CNRS France
University of Eastern Finland Finland
University of Dundee United Kingdom
Imperial College London United Kingdom
Eberhard Karls Universität Tübingen Germany
Kobenhavns Universitet Denmark

Academia

A.O.U. Città della Salute e della Scienza di Torino Italy
UMCG – Groningen The Netherlands
CHRU Lille France
LUMC – Leiden The Netherlands
VUmc – Amsterdam The Netherlands

University hospitals

Institut de Recherches Servier France
Janssen Pharmaceutica NV Belgium
Novo Nordisk A/S Denmark
Sanofi-Aventis Deutschland GMBH Germany

Pharmaceutical Industries (EFPIA)

Small and Medium-sized Enterprises

SCIPROM Sàrl Switzerland
Lipotype GmbH Germany